Clinical benefit analysis of prophylactic use of PEG-rhG-CSF in postoperative adjuvant chemotherapy for stage Ⅱ-111 A wild-type NSCLC with completely resected EGFR
Clinical benefit analysis of prophylactic use of PEG-rhG-CSF in postoperative adjuvant chemotherapy for stage Ⅱ-111 A wild-type NSCLC with completely resected EGFR
Objective To investigate the clinical benefit of prophylactic use of pegylated recombinant human granulocytic colony stimula-ting factor(PEG-rhG-CSF)in postoperative adjuvant chemotherapy for stage Ⅱ-Ⅲ A epidermal growth factor receptor(EGFR)wild-type non-small cell lung cancer(NSCLC)after complete surgical resection.Methods Ninety patients with EGFR wild-type NSCLC who underwent complete surgical resection and postoperative adjuvant chemotherapy at Affiliated Hospital of Guangdong Medical University from February 2019 to February 2021 were prospectively selected as the study subjects.According to the random number table method,the patients were divided into the observation group and the control group,with 45 cases in each group.The control group received prophylactic use of recombinant human granulo-cytes(rhG-CSF),while the observation group received prophylactic use of PEG-rhG-CSF.Patients were followed up for 3 months,and the white blood cell count,neutrophil count levels before treatment and after 1,3,5,and 10 days of treatment,and the incidence of leukopenia and neutropenia were compared between the two groups,adverse reactions after chemotherapy were recorded during the follow-up period for two groups.Results There were no statistically significant differences in the WBC count level between the two groups before treatment,after 1,3 and 5 days of treatment(P＞0.05);after 10 days of treatment,the WBC count level of the study group was(5.65±1.11)×109/L,which was higher than that of the control group[(4.66±1.08)×109/L],the difference was statistically significant(P＜0.05).There were no statistical-ly significant differences in neutrophil count level between the two groups before treatment,after 1,3 and 5 d of treatment(P＞0.05);after 10 d of treatment,the neutrophil count level of the study group was(3.61±1.51)×109/L,which was higher than that of the control group[(2.65 ±1.46)×109/L],the difference was statistically significant(P＜0.05).The proportions of grade 2 and 3 leukopenia and neutropenia in the study group were 15.56％,11.11％,which were lower than those of the control group(35.56％,42.22％),the differences were statistically significant(P＜0.05).There were no statistically significant differences in skeletal muscle pain,fatigue,infection,fever and abnormal gastroin-testinal reaction between the two groups(P＞0.05).Conclusion For patients with stage Ⅱ-ⅢA non-small cell lung cancer with EGFR after complete surgical resection,prophylactic use of PEG-rhG-CSF in postoperative adjuvant chemotherapy can increase the level of leukocyte count and neutrophil count,and reduce the occurrence of leukopenia and neutropenia,and help improve the immune function and prognosis of patients.
维普
万方数据